ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2026

Abstract Number: 2496

Examining the Risk of Pediatric Uveitis Relapse After Discontinuation of Long-Term Systemic Immunosuppressive Therapy in a Retrospective Cohort

Carson Hartlage1, Michael Wagner2, Scott Vennemeyer1, Alexandra Duell3, Virginia Utz3, Megan Quinlan-Waters3 and Sheila Angeles-Han4

Affiliations: 1University of Cincinnati College of Medicine, Cincinnati, OH, 2Cincinnati Children's Hospital Medical Center, Cincinnati, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Cincinnati Children's Hospital, Cincinnati, OH

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2026

Keywords: Eye Disorders, Pediatric rheumatology

Session Information

Date: Tuesday, November 10, 2026

Title: (2483-2518) Pediatric Rheumatology - Clinical Poster C

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Autoimmune uveitis is a chronic, relapsing condition that carries risk of long-term visual impairment and often requires prolonged systemic immunosuppressive therapy (IMT). ACR guidelines recommend two years of sustained disease control before tapering therapy. Previous studies report high rates of relapse after treatment discontinuation. We aimed to evaluate the risk of uveitis relapse after discontinuation of systemic IMT in a pediatric cohort. 

Methods: For this retrospective study, we used data from the Longitudinal Outcomes of Childhood Uveitis Study (LOCUS) registry and linked electronic health records to identify children with uveitis (ICD-10 diagnosis codes) who discontinued or tapered IMT after achieving uveitis quiescence. Inclusion criteria: 1) received IMT for at least 1 year; 2) had at least one ophthalmic exam in the year prior and one within the year following IMT discontinuation; and 3) had no ophthalmic exam indicating active uveitis in the year prior to IMT discontinuation. For patients with multiple IMT periods, only the first was considered. The primary outcome was active uveitis per Standardization of Uveitis Nomenclature (SUN) criteria. Patients were followed from the date of IMT discontinuation until uveitis relapse, re-initiation of systemic IMT, or 1 year of follow-up. Time to relapse was evaluated using Kaplan-Meier survival curves with log-rank testing, and exploratory comparisons between groups were performed using Wilcoxon rank-sum tests for continuous variables and Fisher’s exact tests for categorical variables.

Results: Our cohort included 25 patients with uveitis who discontinued IMT after at least 1 year of treatment and inactive uveitis (76% female; 88% white; median age at index: 8.3 years), of whom 24 (96%) had JIA (Table 1). Over 1 year of follow-up, 12 (48%) experienced relapse (median time: 108 days), and 8 (32%) remained relapse-free off IMT for 1 year (Figure 1). Of the remaining 5 patients, 2 restarted IMT due to arthritis relapse, 1 changed IMT due to intolerance, and 2 were still tapering. No significant difference in survival was observed by IMT treatment regimen (p=0.36; Figure 2). Additionally, there were no significant differences in age at index, age at initial uveitis diagnosis, or duration of IMT therapy between patients who relapsed and those who remained relapse-free at 1 year (p=0.53, 0.48, 0.12, respectively; Table 1). 

Conclusion: Consistent with prior studies, children with autoimmune uveitis face a substantial risk of relapse within 1 year of discontinuing systemic IMT, supporting cautious IMT withdrawal and close monitoring after discontinuation. Further research is needed to identify predictors of sustained remission and guide strategies for treatment tapering and discontinuation in pediatric uveitis. 

Supporting image 1Table 1. Cohort demographic and clinical characteristics. P-values were derived from Wilcoxon rank-sum tests for continuous variables and Fisher’s exact tests for categorical variables. IQR: inter-quartile range

Supporting image 2Figure 1. Swimmer plot of medication and ophthalmic exam history during follow-up for patients with inactive disease at time of immunosuppressive therapy (IMT) discontinuation.

Supporting image 3Figure 2. Survival curves by immunosuppressive therapy (IMT) group for patients with inactive disease at IMT discontinuation. P-value was dervied from log-rank testing.


Disclosures: C. Hartlage: None; M. Wagner: None; S. Vennemeyer: None; A. Duell: None; V. Utz: None; M. Quinlan-Waters: None; S. Angeles-Han: Cabaletta Bio, 12,.

To cite this abstract in AMA style:

Hartlage C, Wagner M, Vennemeyer S, Duell A, Utz V, Quinlan-Waters M, Angeles-Han S. Examining the Risk of Pediatric Uveitis Relapse After Discontinuation of Long-Term Systemic Immunosuppressive Therapy in a Retrospective Cohort [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/examining-the-risk-of-pediatric-uveitis-relapse-after-discontinuation-of-long-term-systemic-immunosuppressive-therapy-in-a-retrospective-cohort/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/examining-the-risk-of-pediatric-uveitis-relapse-after-discontinuation-of-long-term-systemic-immunosuppressive-therapy-in-a-retrospective-cohort/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology